Develops CARVYKTI for multiple myeloma treatment.
Dec 2025Revenue $1.03B/yrExpenses $1.17B/yr
No trendCash runway ≈ 7.0 years from Dec 2025
Figures by year
When will Legend Biotech be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $1.03B and expenses $1.17B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.03B | $1.17B | −$137M |
| Dec 2024 | $627M | $937M | −$310M |
| Dec 2023 | $285M | $813M | −$528M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.